A trial of RVT-103 for the treatment Alzheimer's disease and Lewy-body dementia.
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Donepezil (Primary) ; Donepezil/glycopyrrolate (Primary) ; Glycopyrrolate (Primary) ; Trospium chloride (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- 20 Jul 2017 Trial design presented at the Alzheimer's Association International Conference 2017
- 13 Jun 2017 Results published in an Axovant Sciences Media Release
- 13 Jun 2017 According to an Axovant Sciences media release, the company is planning a RVT-104 proof of concept study (see profile 285954) based on data from this trial. This trial measured subject nausea in 48 healthy, elderly subjects.